PFE — Pfizer Inc. stock price, charts and financials

QT53Pfizer Inc.

Pfizer Inc. (NYSE: PFE) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
27.78
-0.01-0.04%
OverviewShort InterestFilings
PFEQT53Pfizer Inc.·NYSE
27.78-0.04%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
GILD-0.68%$145.65BMY-0.43%$64.41NVO-1.33%$44.56AMGN-0.48%$391.27AZN-1.94%$156.94SNY-0.72%$42.85GSK+0.19%$48.63NVS-0.16%$137.48
Snapshot
IndexS&P 500P/E36.55EPS (ttm)0.76Insider Own0.11%Shs Outstand5.70BPerf Week-2.70%
Market Cap158.33BForward P/E9.60EPS next Y2.89Insider Trans1.69%Shs Float5.69BPerf Month2.70%
Enterprise Value209.83BPEG-EPS next Q0.79Inst Own84.38%Short Float2.62%Perf Quarter8.09%
Income4.33BP/S2.49EPS this Y291.35%Inst Trans0.00%Short Ratio3.56Perf Half Y2.28%
Sales63.70BP/B1.85EPS next Y-2.67%ROA2.16%Short Interest149.27MPerf YTD11.57%
Book/sh15.00P/C13.53EPS next 5Y-4.84%ROE4.89%52W High29.21 -4.90%Perf Year13.16%
Cash/sh2.05P/FCF14.76EPS past 3/5Y-37.12% -3.51%ROIC9.33%52W Low23.58 17.81%Perf 3Y-22.36%
Dividend Est.1.72 (6.19%)EV/EBITDA16.62Sales past 3/5Y-14.56% 8.48%Gross Margin71.32%Volatility1.61% 1.88%Perf 5Y-39.70%
Dividend TTM1.72 (6.19%)EV/Sales3.29EPS Y/Y TTM-46.10%Oper. Margin25.08%ATR (14)0.59Perf 10Y-16.53%
Dividend Ex-DateJul 24, 2026Quick Ratio0.96Sales Y/Y TTM0.11%Profit Margin6.81%RSI (14)53.75Recom2.64
Dividend Gr. 3/5Y2.44% 2.50%Current Ratio1.27EPS Q/Q-1.28%SMA20-0.39%Beta0.28Target Price27.80
Payout225.72%Debt/Eq0.78Sales Q/Q2.60%SMA506.35%Rel Volume0.68Prev Close27.79
Employees75,000LT Debt/Eq0.74EarningsNov 03SMA2006.07%Avg Volume42.05MPrice27.78
IPO DateJun 01, 1972Option/ShortYes / YesEPS/Sales Surpr.12.88% 4.41%Net Debt/EBITDA4.93Volume28,599,468Change-0.04%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedGuggenheimBuy$35 → $31
Jul-06-26DowngradeHSBCBuy → Hold$29 → $28
Jun-10-26UpgradeRBC CapitalUnderperform → Sector Perform
May-27-26ReiteratedUBSNeutral$25 → $27
May-14-26ReiteratedWolfe Research$25 → $26
Mar-17-26ReiteratedMorgan StanleyEqual Weight$28 → $27
Mar-09-26ReiteratedBMO CapitalOutperform$36 → $30
Mar-02-26UpgradeArgus ResearchHold → Buy
Feb-24-26ReiteratedRBC CapitalSector Perform$44 → $25
Feb-19-26InitiatedBarclaysUnderweight$32 → $25
Latest News· Times ET
Sep-09-26
Sep-09-2604:41PM
What Eli Lilly Was Telling You While It Rationed Its Own LaunchesYahoo
05:15AM
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?zacks.com
05:04AM
How a 74-Year-Old Collects $8,900 a Month Without Selling a Single Share247wallst.com
04:27AM
Buy 5 S&P500 IDEAL 'Safer' September Dividend Dogsseekingalpha.com
Sep-08-26
Sep-08-2612:34PM
Why Pfizer Stock Was so Healthy in Augustfool.com
08:45AM
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Nowfool.com
06:00AM
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conferencebusinesswire.com
05:31AM
Lilly Builds Neuroscience into a New Long-Term Growth Driverzacks.com
04:30AM
Dividend Harvesting Portfolio Week 288: $28,800 Allocated, $3,289.51 In Projected Dividendsseekingalpha.com
Sep-07-26
Sep-07-2609:00AM
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now247wallst.com
07:30AM
This Is What I'd Do With Pfizer Stock Right Nowfool.com
Sep-04-26
Sep-04-2610:30AM
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?fool.com
05:42AM
Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?247wallst.com
Sep-03-26
Sep-03-2610:45AM
3 Things You Need to Know If You Buy Pfizer Stock Todayfool.com
09:17AM
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billionbenzinga.com
Company

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Ownership
Total institutional ownership84.38%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue63,69662,57963,627——————
Cost of Goods Sold Incl. D&A18,26718,56521,781——————
Gross Profit45,42944,01441,846——————
Selling, General and Administrative Excl. Other13,29213,34614,730——————
Research and Development12,79011,97610,738——————
Other Operating Expense3,3713,255-105——————
Operating Income15,97615,43716,483——————
Interest Expense2,6982,6713,091——————
Unusual Expense
—————————
Non-Operating Income (Expense)-9,069-5,246-5,369——————
Net Income Before Taxes4,2097,5208,023——————
Income Taxes-164-266-28——————
Consolidated Net Income4,3357,7708,020——————
Net Income From Continuing Operations4,3737,7868,051——————
Net Income4,3357,7708,020——————
EPS (Recurring)0.761.361.42——————
EPS (Basic, Before Extraordinaries)0.761.361.42——————
EPS (Diluted)0.761.361.41——————
EBITDA12,62415,09618,127——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio36.5518.3118.82——————
Price To Sales Ratio2.492.262.36——————
Gross Margin71.3270.3365.77——————
Operating Margin25.0824.6725.91——————
Net Margin6.8112.4212.60——————
Shares Outstanding5,6995,6835,664——————
Market Capitalization158,318141,507150,266——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$29.88$28.02$26.16$24.29$22.43● Close Price0.00M0.74M1.48M2.22M2.96MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BOURLA ALBERTChairman & CEOAug 12 '26Buy26.3438,0001,000,920429,173Aug 12
DAMICO JENNIFER B.SVP & ControllerAug 05 '26Sale25.403,27883,26128,611Aug 06
Buckley Mortimer JDirectorAug 05 '26Buy25.5237,632960,36937,632Aug 05
BLAYLOCK RONALD EDirectorAug 05 '26Buy25.4639,231998,82166,938Aug 05
DAMICO JENNIFER B.SVP & ControllerJun 09 '26Sale25.702,00051,40031,397Jun 10
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25 '26Option Exercise33.82122,9074,156,715282,186Feb 27
DAMICO JENNIFER B.SVP & ControllerFeb 25 '26Option Exercise33.8217,558593,81229,744Feb 27
BOURLA ALBERTChairman & CEOFeb 25 '26Option Exercise33.82491,62616,626,791864,215Feb 27
McDermott MichaelExecutive Vice PresidentFeb 25 '26Option Exercise33.8237,9251,282,624114,534Feb 27
Fonseca LidiaExecutive Vice PresidentFeb 25 '26Option Exercise33.8256,8881,923,952101,579Feb 27
SAHNI PAYALExecutive Vice PresidentFeb 25 '26Option Exercise33.8256,8881,923,95282,816Feb 27
DAMICO JENNIFER B.SVP & ControllerMar 04 '25Sale25.932,50064,82511,850Mar 06
DAMICO JENNIFER B.SVP & ControllerFeb 27 '25Option Exercise31.3122,416701,84531,063Mar 03
SUSMAN SALLYExecutive Vice PresidentFeb 27 '25Option Exercise31.3185,1822,667,048250,866Mar 03
SAHNI PAYALExecutive Vice PresidentFeb 27 '25Option Exercise31.3119,054596,58144,242Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.